361 related articles for article (PubMed ID: 21996197)
1. Tolerance of enteric-coated mycophenolate sodium in combination with calcineurin inhibitor in kidney transplant recipients: Polish experience.
Gozdowska J; Urbanowicz AL; Galazka Z; Chmura A; Durlik M
Transplant Proc; 2011 Oct; 43(8):2946-9. PubMed ID: 21996197
[TBL] [Abstract][Full Text] [Related]
2. A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients.
Kamar N; Rostaing L; Cassuto E; Villemain F; Moal MC; Ladrière M; Barrou B; Ducloux D; Chaouche K; Quéré S; Di Giambattista F; Be F
Clin Nephrol; 2012 Feb; 77(2):126-36. PubMed ID: 22257543
[TBL] [Abstract][Full Text] [Related]
3. Enteric-coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal-transplant recipients compared with mycophenolate mofetil.
Feng JJ; Zhang LW; Zhao P; Bow LM; Tian J
Int J Clin Pract Suppl; 2015 May; (183):1-7. PubMed ID: 26176848
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
Bilodeau JF; Montambault P; Wolff JL; Lemire J; Masse M
Transplant Proc; 2009 Nov; 41(9):3683-9. PubMed ID: 19917367
[TBL] [Abstract][Full Text] [Related]
5. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
[TBL] [Abstract][Full Text] [Related]
6. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation.
Langone A; Shihab F; Pankewycz O; Doria C; Wiland A; McCague K; Chan L
Clin Transplant; 2014 Sep; 28(9):961-7. PubMed ID: 24893821
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
Ortega F; Sánchez-Fructuoso A; Cruzado JM; Gómez-Alamillo JC; Alarcón A; Pallardó L; Morales JM; Oliver J; Guinea G;
Transplantation; 2011 Aug; 92(4):426-32. PubMed ID: 21760569
[TBL] [Abstract][Full Text] [Related]
8. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China.
Xu L; Cai M; Shi BY; Li ZL; Li X; Jin HL
Transplant Proc; 2014 Jun; 46(5):1362-5. PubMed ID: 24935300
[TBL] [Abstract][Full Text] [Related]
9. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.
Massari P; Duro-Garcia V; Girón F; Hernández E; Juárez F; Castro C; Toledo M;
Transplant Proc; 2005 Mar; 37(2):916-9. PubMed ID: 15848574
[TBL] [Abstract][Full Text] [Related]
10. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil.
Sánchez Fructuoso A; Calvo N; Moreno MA; Giorgi M; Conesa J; Barrientos A
Transplant Proc; 2007 Sep; 39(7):2194-6. PubMed ID: 17889135
[TBL] [Abstract][Full Text] [Related]
11. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
Budde K; Glander P; Diekmann F; Dragun D; Waiser J; Fritsche L; Neumayer HH
Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
[TBL] [Abstract][Full Text] [Related]
12. Renal transplant patients with gastrointestinal intolerability to mycophenolate mofetil: conversion to enteric-coated mycophenolate sodium.
Calvo N; Sanchez-Fructuoso AI; Conesa J; Moreno A; Barrientos A
Transplant Proc; 2006 Oct; 38(8):2396-7. PubMed ID: 17097945
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic).
Budde K; Knoll G; Curtis J; Chan L; Pohanka E; Gentil M; Seifu Y; Marrast AC; Neumayer HH;
Clin Nephrol; 2006 Aug; 66(2):103-11. PubMed ID: 16939066
[TBL] [Abstract][Full Text] [Related]
14. Quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.
Cofan F; Rosich E; Arias M; Torregrosa V; Oppenheimer F; Campistol JM
Transplant Proc; 2007 Sep; 39(7):2179-81. PubMed ID: 17889130
[TBL] [Abstract][Full Text] [Related]
15. Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis.
Salvadori M; Bertoni E; Budde K; Holzer H; Civati G; Lien B; Arns W
Transplant Proc; 2010 May; 42(4):1325-8. PubMed ID: 20534293
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of enteric-coated mycophenolate sodium in patients with de novo and maintenance renal transplantation.
Qin Y; Zhang F; Shen B; Liu Y; Qiu J; Guo Y; Fan Y
Int J Clin Pract Suppl; 2014 Apr; (181):17-22. PubMed ID: 24673715
[TBL] [Abstract][Full Text] [Related]
18. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study.
Langone AJ; Chan L; Bolin P; Cooper M
Transplantation; 2011 Feb; 91(4):470-8. PubMed ID: 21245794
[TBL] [Abstract][Full Text] [Related]
19. Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation.
Shehata M; Bhandari S; Venkat-Raman G; Moore R; D'Souza R; Riad H; Bakran A; Baker R; Needham C; Andrews C
Transpl Int; 2009 Aug; 22(8):821-30. PubMed ID: 19386081
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of tolerance and safety of conversion from mycophenolate mofetil to enteric-coated mycophenolic acid in renal transplant recipients.
Qiao LW; Qu QS; Jiang X
J Biol Regul Homeost Agents; 2017; 31(1):141-146. PubMed ID: 28337883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
